AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Teva Pharmaceutical Industries Ltd. Earnings Release 2004

Oct 24, 2004

7082_rns_2004-10-24_b4489147-3c89-4830-a9a5-2c7924fff855.htm

Earnings Release

Opens in your device viewer


C002	טבע תעשיות פרמצבטיות בע"מ		2
Public	TEVA- PHARMACEUTICAL INDUSTRIES LTD.
	2529	Corporation no: 520013954
	Stock Exchange/Market: טבע

	310
	380	P.O.B 3190 , Petach Tikva 49131 , ,
	Tel: 03-9267297 , 03-9267281 Fax: 03-9267429
	E.mail address: [email protected]	Date of transmission: 24/10/2004

		Time of broadcast: 08:55 08:53:11
		Reference: 2004-02-121368



Israel Securities Authority		Tel Aviv Stock Exchange
www.isa.gov.il		www.tase.co.il

Immediate ReportRegulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000


The corporation is a foreign private issuer as defined by U.S. Securities Laws.
Attached hereto is a report on TEVA ANNOUNCES THIRD QUARTER GLOBAL IN-MARKET SALES OF COPAXONE INCREASED 34% TO $242 MILLION
CopaxoneSalesQ304211004_isa.pdf


Please find attached a press release and its non-binding hebrew translation, provided for convenience purposes only
References of previous documents relating to this matter(the reference does not constitute incorporation by reference):

Previous name of reporting entity:
Date of revision of form structure: 08/09/2004
- - -
Name of the Signatory : Suesskind Dan Position of Signatory in the reporting corporation: Chief Financial Officer
Basel Telephone: 02-5892840 , Facsimile: 02-5892839 , E-mail: [email protected]